the effect of bifid triple viable on immune function of patients with ulcerative colitis裂成两半的三重效果可行的溃疡性结肠炎患者的免疫功能.pdfVIP

Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2012, Article ID 404752, 9 pages doi:10.1155/2012/404752 Research Article The Effect of Bifid Triple Viable on Immune Function of Patients with Ulcerative Colitis Guohua Li, Sheng Zeng, Wangdi Liao, and Nonghua Lv Department of Gastroenterology, The First Affi liated Hospital of Nanchang University, Nanchang 330006, China Correspondence should be addressed to Guohua Li, liguohua98@ Received 9 April 2012; Revised 12 June 2012; Accepted 2 July 2012 Academic Editor: Antonio Gasbarrini Copyright © 2012 Guohua Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. To study effect and its mechanism of Bifid Triple Viable for initially treating ulcerative colitis with 5-aminosalicylic acid. Methods. 82 patients, who were firstly diagnosed as ulcerative colitis, were randomized into experiment group (41 cases, treated with Bifid Triple Viable and Etiasa) and control group (41 cases, treated with Etiasa). The clinic symptom score, colon mucosa inflammation score, and some immune indices were detected and compared between two groups before and two months after treatment. Results. Two months after treatment, the clinical symptom score, colon mucosa inflammation score, and IL- 1β expression in colon mucosa decreased significantly (P 0.01), and IL-10 and IgA expressions in colon mucosa increased significantly (P 0.01). Those differences were more marked in experiment group than control group (P 0.05). However, peripheral blood T cell subgroup, immunoglobulins, and complements had no significant difference betwee